NEW YORK – Immune profiling firm ImmunoScape said Wednesday that it has closed a $14 million funding round.
The Singapore-based company said it would use the funds to grow its Singapore team and continue its expansion into the US market, including scaling up its recently launched San Diego lab facility.
The round was led by existing investors Anzu Partners, University of Tokyo Edge Capital Partners (UTEC), and new investor EDBI, an investment arm of the Economic Development Board of Singapore. It brings the company's total funding raised in the past year to $25 million.
ImmunoScape's platform uses tetramers, oligomers containing major histocompatibility complexes (MHCs) loaded with peptide antigens of interest, to profile patient immune responses. These tetramers allow the company to present antigen peptides that may figure in conditions like cancer or infectious disease. It can then monitor patterns of T-cell binding to those peptides, looking for differences between, for instance, responders and non-responders to a therapy or changes in T-cell binding over the course of an individual's treatment regimen.
"ImmunoScape is a global company with a highly differentiated platform that can change the way lifesaving treatments are developed," David Michael, managing partner at Anzu Partners, said in a statement. “We are delighted to help bring this technology to biopharma leaders and support drug development in immuno-oncology and infectious disease."